Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

- PMLiVE

Generic threat looms to J&J’s blockbuster Zytiga in US

Impact could also be felt by Pfizer

- PMLiVE

Digital tech from Autolus and Oxford BioMedica to speed advanced therapies

UK funds efforts to make country a leader in cell and gene therapy

- PMLiVE

NICE lung cancer backing for Keytruda is biggest expansion yet

Access will be via the Cancer Drugs Fund until 2019 review

- PMLiVE

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Daurismo cleared for those too frail for chemo

- PMLiVE

Five questions guiding the way to actual patient-centricity

‘91% of employees in the pharma industry believe it is very or extremely important for pharma to deliver on its patient-focused missions’

- PMLiVE

FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease

Approval adds to growing US portfolio

- PMLiVE

PEGASUS WINS AT PHARMATIMES COMMUNICATIONS TEAM OF THE YEAR AWARDS 2018

Pegasus was also highly commended in the NHS Communications Team category

Inizio

- PMLiVE

As Brexit looms, UK medicines agency head Hudson announces departure

Search for successor must start in early 2019

- PMLiVE

Reference price bill tabled in US House and Senate

The new measure could reduce median drug prices by around 43%

- PMLiVE

The power of behaviour change lies in the basics

‘Only with robust benchmarking can we address specific behaviour and make the right interventions to nudge the change’ 

Deal Watch October 2018

When writing this bimonthly edition of Medius’s Deal Watch I have been struck by how often the words 'it’s unusual...' have appeared. Most months we focus on the usual and...

- PMLiVE

Is AstraZeneca looking for its next CEO?

Shareholders said to want succession plan in place

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links